DK3237001T3 - Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer - Google Patents

Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer Download PDF

Info

Publication number
DK3237001T3
DK3237001T3 DK15823805.5T DK15823805T DK3237001T3 DK 3237001 T3 DK3237001 T3 DK 3237001T3 DK 15823805 T DK15823805 T DK 15823805T DK 3237001 T3 DK3237001 T3 DK 3237001T3
Authority
DK
Denmark
Prior art keywords
antibodies
liquid compositions
pharmaceutical products
stable liquid
stable
Prior art date
Application number
DK15823805.5T
Other languages
English (en)
Inventor
Susanne Joerg
Kathrin Serno-Schersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3237001T3 publication Critical patent/DK3237001T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15823805.5T 2014-12-22 2015-12-21 Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer DK3237001T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095210P 2014-12-22 2014-12-22
PCT/IB2015/059836 WO2016103153A1 (en) 2014-12-22 2015-12-21 Pharmaceutical products and stable liquid compositions of il-17 antibodies

Publications (1)

Publication Number Publication Date
DK3237001T3 true DK3237001T3 (da) 2024-04-15

Family

ID=55135471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15823805.5T DK3237001T3 (da) 2014-12-22 2015-12-21 Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer

Country Status (27)

Country Link
US (2) US11801300B2 (da)
EP (2) EP4372005A2 (da)
JP (4) JP6770974B2 (da)
KR (3) KR102506173B1 (da)
CN (5) CN113876947A (da)
AR (1) AR103173A1 (da)
AU (1) AU2015370522B2 (da)
BR (1) BR112017013240A2 (da)
CA (1) CA2971800A1 (da)
CL (1) CL2017001638A1 (da)
CO (1) CO2017005950A2 (da)
DK (1) DK3237001T3 (da)
EA (1) EA033824B1 (da)
EC (1) ECSP17047155A (da)
FI (1) FI3237001T3 (da)
HR (1) HRP20240253T1 (da)
IL (3) IL310604A (da)
LT (1) LT3237001T (da)
MX (1) MX2017008412A (da)
PE (1) PE20170952A1 (da)
PH (1) PH12017500966A1 (da)
PT (1) PT3237001T (da)
RS (1) RS65387B1 (da)
SG (1) SG11201703828VA (da)
TN (1) TN2017000181A1 (da)
TW (1) TW201641104A (da)
WO (1) WO2016103153A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
WO2018015880A1 (en) * 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
TW201919582A (zh) * 2017-07-24 2019-06-01 美商再生元醫藥公司 穩定化之抗體組合物及其製法
KR20200083996A (ko) * 2017-11-02 2020-07-09 노파르티스 아게 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
JP2021504482A (ja) * 2017-11-30 2021-02-15 バイオ−テラ ソリュ−ションズ，エルティーディー． Ｉｌ‐６関連疾患を治療するためのヒト化抗体の液体製剤
CN111303283A (zh) * 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
RU2754760C2 (ru) * 2019-04-02 2021-09-07 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция анти-il17a антитела и ее применение
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CN110124030A (zh) * 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
WO2021053591A1 (en) 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
JP2023502103A (ja) 2019-11-19 2023-01-20 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2022258045A1 (zh) * 2021-06-11 2022-12-15 山东先声生物制药有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN113999300B (zh) * 2021-12-13 2022-09-13 青岛润达生物科技有限公司 一种高效提取卵黄抗体的复合沉降剂及方法
CN114452383B (zh) * 2022-02-17 2023-06-06 中国中医科学院中药研究所 司库奇尤单抗在治疗糖尿病溃疡中的用途
CN117883376B (zh) * 2024-03-14 2024-06-25 北京四环生物制药有限公司 含重组人白细胞介素-2的药物制剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
PT1441589E (pt) 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
EP2277522B1 (en) 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methods for increasing or decreasing bone density and identifying molecules
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20090238820A1 (en) * 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
BRPI0807205A2 (pt) 2007-02-02 2014-07-22 Novartis Ag Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
JP2012533548A (ja) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
US9717791B2 (en) * 2010-10-08 2017-08-01 Novartis Ag Methods of treating psoriasis using IL-17 antibody
EP3757126A1 (en) * 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
EP2783014A1 (en) * 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
EP3156073A1 (en) 2012-03-07 2017-04-19 Eli Lilly and Company Il-17 antibody formulation
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations

Also Published As

Publication number Publication date
JP6770974B2 (ja) 2020-10-21
BR112017013240A2 (pt) 2018-02-06
EA201791422A1 (ru) 2017-10-31
CN114452381A (zh) 2022-05-10
AU2015370522B2 (en) 2018-05-10
IL287328A (en) 2021-12-01
KR20170095878A (ko) 2017-08-23
EA033824B1 (ru) 2019-11-29
TW201641104A (zh) 2016-12-01
EP4372005A2 (en) 2024-05-22
LT3237001T (lt) 2024-04-25
WO2016103153A1 (en) 2016-06-30
FI3237001T3 (fi) 2024-03-22
AU2015370522A1 (en) 2017-06-01
CO2017005950A2 (es) 2017-08-31
CN113855800A (zh) 2021-12-31
CN107257692A (zh) 2017-10-17
CN113876947A (zh) 2022-01-04
ECSP17047155A (es) 2019-02-28
US11801300B2 (en) 2023-10-31
SG11201703828VA (en) 2017-07-28
IL252141A0 (en) 2017-07-31
US20170368174A1 (en) 2017-12-28
IL310604A (en) 2024-04-01
PE20170952A1 (es) 2017-07-13
IL287328B1 (en) 2024-03-01
EP3237001A1 (en) 2017-11-01
JP2023113906A (ja) 2023-08-16
CL2017001638A1 (es) 2018-04-13
PH12017500966A1 (en) 2017-10-18
JP2021119165A (ja) 2021-08-12
EP3237001B1 (en) 2024-02-07
KR20230173742A (ko) 2023-12-27
US20240173404A1 (en) 2024-05-30
CN114452380A (zh) 2022-05-10
KR102506173B1 (ko) 2023-03-07
CN107257692B (zh) 2021-11-19
MX2017008412A (es) 2017-10-19
KR20230037677A (ko) 2023-03-16
JP2018502910A (ja) 2018-02-01
JP6878524B2 (ja) 2021-05-26
TN2017000181A1 (en) 2018-10-19
JP2020011963A (ja) 2020-01-23
IL252141B (en) 2021-12-01
HRP20240253T1 (hr) 2024-05-10
CA2971800A1 (en) 2016-06-30
RS65387B1 (sr) 2024-04-30
AR103173A1 (es) 2017-04-19
KR102614921B1 (ko) 2023-12-19
PT3237001T (pt) 2024-04-16

Similar Documents

Publication Publication Date Title
DK3237001T3 (da) Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer
DK3827845T3 (da) Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
DK3506884T3 (da) Sammensætninger til indgivelse af medicin og anvendelser af disse
DK3690056T3 (da) Fremgangsmåder og produkter til fremstilling og indgivelse af nukleinsyre
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3039146T3 (da) Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
DK3212230T3 (da) Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
DK3237436T3 (da) Peptider og nanopartikler til intracellulær indgivelse af molekyler
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3364958T3 (da) Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
BR112016026879A2 (pt) Composição farmacêutica líquida
DK3102184T3 (da) Stabile formuleringer af peptider og fremgangsmåder til fremstilling
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3129019T3 (da) Medicinsk anvendelse af artemisinin-forbindelser og gephyrin-agonister
BR112017008125A2 (pt) redução da viscosidade de formulações farmacêuticas
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3237054T3 (da) Indretning til fremstilling og påføring af en medicinsk substans
DK2958573T3 (da) Farmaceutiske formuleringer af nitrit og anvendelser deraf
DK3137479T3 (da) Oligonukleotidsammensætninger og fremgangsmåder til fremstilling af disse
DK3387019T3 (da) Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
DK3242564T3 (da) Fremgangsmåde til fremstilling af bløde holdbare produkter